Combination stacks // dedicated brief
Ipamorelin and CJC-1295: The Common Research Stack
Why two GH peptides get paired, what the evidence for each actually says, and the line between the combination's rationale and its (absent) trial record.
In plain English
The ipamorelin cjc-1295 pairing is the most common growth-hormone-peptide "stack" you will see discussed, and the logic is simple once you see it. Growth hormone gets released through two different switches. Ipamorelin presses one of them (the ghrelin receptor) and produces a short, sharp pulse. CJC-1295 presses the other (the GHRH receptor) and produces a long, slow elevation. Because they work through different doors, combining them is meant to give a bigger, longer GH signal than either alone — a quick spike riding on top of a sustained rise. That is the theory, and the mechanism is real [1]. What is missing is a trial: nobody has tested the actual combination, in people, for any specific outcome. Everything claimed about the stack is stitched together from each peptide's separate evidence. This brief lays out both peptides, what the data really support, and where the honest gaps are.
What is cjc 1295 ipamorelin
"CJC-1295 ipamorelin" refers to the co-administration of two distinct peptides that raise growth hormone through complementary mechanisms. Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist — a five-amino-acid peptide that pulses GH cleanly, without the cortisol or prolactin spillover of older GH-releasing peptides [1]. CJC-1295 is a long-acting analog of growth-hormone-releasing hormone (GHRH) that acts on the separate GHRH receptor. They are sometimes sold pre-blended in a single research vial, but they remain two different molecules with two different pharmacologies, and only one of them (ipamorelin) is the subject of this site. CJC-1295 appears here purely as the research-stack partner.
Does cjc-1295 ipamorelin work?
Each peptide moves growth hormone on its own; the combination has never been formally tested. On the GHRH side, a single subcutaneous dose of CJC-1295 in healthy adults produced 2- to 10-fold GH increases for six-plus days and 1.5- to 3-fold sustained IGF-1 elevation, while keeping the natural pulsing rhythm intact [7]. That pulsatility survives even continuous GHRH-pathway stimulation [8], and the durable GH/IGF-1 axis activation has been characterized further [9]. On the ipamorelin side, the molecule reliably pulses GH in animals and humans [1][2] but failed its one human efficacy trial (postoperative ileus) [3]. An observational report in hypogonadal men found combined GHS therapy raised IGF-1 [10] — real biological activity, but not a controlled efficacy trial. So: "works" in the narrow sense of moving GH and IGF-1, yes; "works" in the sense of a proven outcome from the actual combination, not demonstrated.
Is cjc-1295 ipamorelin safe?
The honest answer is that the long-term safety of this combination in humans is uncharacterized. The single human ipamorelin trial logged no compound-specific safety signal over its 7-day window (adverse events 87.5% ipamorelin vs 94.8% placebo) [3], but that is a short, supervised, intravenous setting — not chronic subcutaneous self-use. Two cautions matter at the class level. First, raising the GH/IGF-1 axis is mechanistically tied to IGF-1's growth-promoting activity, a theoretical concern in anyone with cancer risk [13]. Second, a 28-day study of a different ghrelin-receptor agonist found dose-dependent heart-muscle degeneration in rats — a class-level cardiovascular signal, with no equivalent long-duration ipamorelin study to confirm or rule it out [6]. Add unverified gray-market purity, and "safe" is not a word the evidence supports for unsupervised chronic use. Full detail is on the Ipamorelin effects page.
Why the two are paired: the mechanism
The pairing rests on a genuine physiological idea. GHRH analogs and GH-releasing peptides raise growth hormone through separate receptors — the GHRH receptor (cAMP pathway) and GHS-R1a (the ghrelin receptor, calcium pathway) — and the two are synergistic when activated together [1]. The intended picture is a steady GHRH-driven elevation from CJC-1295 with ipamorelin's discrete pulses layered on top, while the body's natural rhythm is preserved rather than flattened — and pulsatility is in fact retained under continuous GHRH stimulation [8]. It is an elegant rationale. It is also, to date, only a rationale: the synergy is inferred from each agent's separate data, not measured in a combination trial.
Ipamorelin vs tesamorelin
Tesamorelin is a different beast in one important way: it is an actual approved drug. Like CJC-1295 and sermorelin, tesamorelin is a GHRH analog (it works on the GHRH receptor), and it is FDA-approved for a single, specific indication — reducing excess visceral abdominal fat in people with HIV-associated lipodystrophy. Ipamorelin, by contrast, is a ghrelin-receptor agonist that has never been approved for anything [11]. So an "ipamorelin vs tesamorelin" comparison is really a comparison between an unapproved research peptide that pulses GH and an approved GHRH analog with a narrow label — different receptors, different regulatory status, and a far deeper human evidence base on the tesamorelin side. They are sometimes discussed as stack partners for the same reason ipamorelin is paired with CJC-1295: GHRP-plus-GHRH complementarity [1].
The bottom line on the stack
The ipamorelin cjc-1295 combination is supported by separate, legitimate single-agent pharmacology and by a coherent mechanistic rationale — but not by a single controlled trial of the combination itself, for any outcome [3][7]. That is the central fact a reader should leave with. The peptides are real, their individual effects on GH and IGF-1 are documented, and the synergy is biologically plausible; the leap to a specific protocol, dose, or promised result is where the evidence runs out. This site documents that evidence and that boundary; it does not sell the stack, recommend it, or provide dosing for it.